Optimum bronchodilator combinations in chronic obstructive pulmonary disease: What is the current evidence?

Drugs

Volumn 72, Issue 3, 2012, Pages 301-308

  Miles, Matthew C ^a   Donohue, James F ^b   Ohar, Jill A ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Beta adrenergic receptor antagonists; Bronchodilators; Chronic obstructive pulmonary disease; Corticosteroids; Dyspnoea; Indacaterol; Inhalation; Muscarinic receptor antagonists; Phosphoric diester hydrolase inhibitors; Quality of life rating scales; Salbutamol; Salmeterol; Tiotropium bromide.

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL; TIOTROPIUM BROMIDE; TULOBUTEROL;

AIRFLOW; ASTHMA; BODY MASS; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HEART ARRHYTHMIA; HUMAN; OUTCOME ASSESSMENT; PNEUMONIA; QUALITY OF LIFE; REVIEW; SPIROMETRY; TACHYCARDIA;

ADMINISTRATION, INHALATION; BRONCHODILATOR AGENTS; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84856693792     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11598580-000000000-00000     Document Type: Review

References (60)

1. World Health Organization. Chronic respiratory diseases: burden of COPD [online]. Available from URL: http://www.who.int/respiratory/copd/burden/en/ index.html [Accessed 2011 Feb 8]
2. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57 (10): 847-52 (Pubitemid 35178607)
3. Seemungal T, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161 (5): 1608-13 (Pubitemid 30329036)
4. Agustí AGN, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21 (2): 347-60 (Pubitemid 36204553)
5. Tockman MS, Anthonisen NR, Wright EC, et al. Airways obstruction and the risk for lung cancer. Ann Int Med 1987; 106 (4): 512-8 (Pubitemid 17095034)
6. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32 (4): 962-9
7. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Int Med 2011; 155 (3): 179-91
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2010 [online]. Available from URL: http://www.goldcopd.org/guidelines-global-strat egy-for-diagnosis-management.html [Accessed 2012 Jan 23]
9. US Department of Health & Human Services. US FDA. FDA approves new drug to treat chronic obstructive pulmonary disease [media release]. 2011 Mar 1 [online]. Available from URL: http://www.fda.gov/NewsEvents/News room/PressAnnouncements/ucm244989.htm [Accessed 2011 Jan 4]
10. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374 (9691): 695-703
11. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebocontrolled blinded comparison with tiotropium. Respir Res 2010; 11 (1): 135
12. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65 (6): 473-9
13. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182 (2): 155-62
14. Renard D, Looby M, Kramer B, et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model- based approaches. Respiratory Research 2011; 12 (1): 54
15. Mahler D, D'Urzo A, Peckitt C, et al. Combining once-daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. Am J Respir Crit Care Med 2011; 183: A1591
16. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med 2011; 105 (5): 719-26
17. Kanner RE, Connett JE, Williams DE, et al. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the lung health study. Am JMed 1999; 106 (4): 410-6 (Pubitemid 29190593)
18. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ 1977; 1 (6077): 1645-8 (Pubitemid 8124466)
19. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350 (10): 1005-12 (Pubitemid 38269277)
20. Cote CG, Pinto-Plata VM, Marin JM, et al. The modified BODE index: validation with mortality in COPD. Eur Respir J 2008; 32 (5): 1269-74
21. Miles MC, Donohue JF, Ohar JA. Combination therapy for COPD: emerging evidence from recent clinical trials. Clin Investig 2011; 1 (6): 879-90
22. Redelmeier DA, Goldstein RS, Min ST, et al. Spirometry and dyspnea in patients with COPD. Chest 1996; 109 (5): 1163-8
23. Niewoehner DE, Collins D, Erbland ML. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med 2000; 161 (4): 1201-5 (Pubitemid 30243830)
24. O'donnel DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158 (5): 1557-65
25. Marco F Di, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003; 21 (1): 86-94
26. Redelmeier DA, Bayoumi AM, Goldstein RS, et al. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997; 155 (4): 1278-82 (Pubitemid 27172771)
27. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011; 37 (4): 784-90
28. Singh SJ, Jones PW, Evans R, et al. Minimum clinically important improvement for the incremental shuttle walking test. Thorax 2008; 63 (9): 775-7
29. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85 (6): 751-8 (Pubitemid 14121920)
30. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 Suppl. 2: 25-31
31. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42 (10): 773-8 (Pubitemid 17142007)
32. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996; 49 (11): 1215-9 (Pubitemid 26386225)
33. Donohue JF. Minimal clinically important differences in COPD lung function: COPD 2005; 2 (1): 111-24
34. Make B, Casaburi R, Leidy NK. Interpreting results from clinical trials: understanding minimal clinically important differences in COPD outcomes. COPD 2005; 2 (1): 1-5 (Pubitemid 40776216)
35. van Noord JA, Aumann J-L, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26 (2): 214-22 (Pubitemid 41079064)
36. van Noord JA, Aumann J-L, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. RespirMed 2010; 104 (7): 995-1004
37. Wang J, Jin D, Zuo P, et al. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirol 2010; 16: 350-8
38. Rabe KF, Timmer W, Sagkriotis A, et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134 (2): 255-62
39. Calverley P, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356 (8): 775-89 (Pubitemid 46294610)
40. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166 (8): 1084-91 (Pubitemid 35178706)
41. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361 (9356): 449-56 (Pubitemid 36173708)
42. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respiratory Journal 2003; 21 (1): 74-81 (Pubitemid 36150304)
43. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone- salmeterol for treatment of chronic obstructive pulmonary disease. Ann Int Med 2007; 146 (8): 545-55 (Pubitemid 351650535)
44. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180 (8): 741-50
45. Ichinose M, Seyama K, Nishimura M, et al. Additive effects of transdermal tulobuterol to inhaled tiotropium in patients with COPD. Respir Med 2010; 104 (2): 267-74
46. Um S-W, Yoo C-G, Kim YW, et al. The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease. J Korean Med Sci 2007; 22 (5): 839-45
47. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit CareMed 2008; 177 (1): 19-26
48. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease. Eur Respir J 2003; 22 (6): 912-9 (Pubitemid 37540641)
49. Tashkin DP, Donohue JF, Mahler D a, et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir Med 2009; 103 (4): 516-24
50. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 1543-54
51. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178 (4): 332-8
52. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364 (12): 1093-103
53. Barnes PJ. Inhaled corticosteroids in COPD: a controversy. Respiration 2010; 80 (2): 89-95
54. Singanayagam A, Chalmers JD, Akram AR, et al. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011; 38 (1): 36-41
55. Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010; 36 (4): 751-7
56. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374 (9691): 712-9
57. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 1993; 306 (6884): 1034-7 (Pubitemid 23105961)
58. Nelson HS, Weiss ST, Bleecker ER, et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129 (1): 15-26 (Pubitemid 43265239)
59. US Department of Health and Human Services. US FDA. FDA drug safety communication: new safety requirements for long-acting inhaled asthma medications called longacting beta-agonists (LABAs) [media release]. 2010 Feb 18 [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatients andProviders/ucm200776.htm [Accessed 2011 Aug 4]
60. Rabe KF. Anticholinergic drugs for the treatment of COPD are safeyare they? Chest 2010; 137 (1): 1-3